Shanghai Fosun Pharmaceutical (Group) , Ltd. Profit Margin

Shanghai Fosun Pharmaceutical (Group) , Ltd. posts a profit margin of 8.33% as of September 2026. That compares with 8.3% in the prior-year period — up 0.4% year over year. That is below the sector sector average of 13.23%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Shanghai Fosun Pharmaceutical (Group) , Ltd.'s profit margin was 8.3%. The latest reading is 8.33% — a 0.4% year-over-year increase (period ending September 2026). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a profit margin near 13.23% is typical. Shanghai Fosun Pharmaceutical (Group) , Ltd.'s 8.33% is lower that level. That is roughly 37.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Shanghai Fosun Pharmaceutical (Group) , Ltd.'s profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 8.33% as of September 2026; use YoY and peer views to separate noise from signal.

Context for SFOSF's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 13.23%), and (3) consistency with growth and profitability. This page covers the first two; Shanghai Fosun Pharmaceutical (Group) , Ltd.'s other metric pages and overview cover the third.